Biomarker Testing and Treatment Strategies in HER2-Overexpressing NSCLC

home / oncview / biomarker-testing-and-treatment-strategies-in-her2-overexpressing-nsclc

Panelists discuss how advancements in biomarker testing and targeted therapies, particularly trastuzumab deruxtecan, are reshaping treatment strategies for HER2-overexpressing non-small cell lung cancer.

EP. 1: An Overview of HER2 Alterations in NSCLC and Implications for Treatment

Rohit Gosain, MD;Rahul Gosain, MD;Benjamin P. Levy, MD

November 8th 2024

Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing methods such as IHC and NGS.

EP. 2: Biomarker Testing in NSCLC: Best Practices for Personalized Medicine

Rohit Gosain, MD;Rahul Gosain, MD;Benjamin P. Levy, MD

November 15th 2024

Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.

EP. 3: T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights

Rohit Gosain, MD;Rahul Gosain, MD;Benjamin P. Levy, MD

November 22nd 2024

Panelists discuss how the evolving treatment landscape for HER2-overexpressing NSCLC, particularly with the introduction of trastuzumab deruxtecan, influences therapeutic strategies and decision-making based on recent clinical trial data.